Top Markets
Coin of the day
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
Rangering i aksjer #24450
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Aksjekurs
$0.78611575
Markedsverdi
$60.45M
Endring (1 dag)
0.00%
Endring (1 år)
-12.06%
Land
NO
Handel Lytix Biopharma AS (LYTIX)

Kategori

Utbytteavkastning for Lytix Biopharma AS (LYTIX)
Lytix Biopharma AS (aksjesymbol: LYTIX) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Lytix Biopharma AS (LYTIX) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH